Iloprost in intensive care medicine:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Bremen
UNI-MED-Verl.
2006
|
| Schriftenreihe: | UNI-MED science
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Literaturangaben |
| Beschreibung: | 112 S. Ill., graph. Darst. |
| ISBN: | 9783895999437 3895999431 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV022824720 | ||
| 003 | DE-604 | ||
| 005 | 20071107 | ||
| 007 | t | ||
| 008 | 070926s2006 gw ad|| |||| 00||| eng d | ||
| 015 | |a 06,A42,1105 |2 dnb | ||
| 016 | 7 | |a 981190383 |2 DE-101 | |
| 020 | |a 9783895999437 |c Pp. : EUR 44.80, sfr 79.20 |9 978-3-89599-943-7 | ||
| 020 | |a 3895999431 |c Pp. : EUR 44.80, sfr 79.20 |9 3-89599-943-1 | ||
| 035 | |a (OCoLC)71336777 | ||
| 035 | |a (DE-599)BVBBV022824720 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE | ||
| 049 | |a DE-355 | ||
| 084 | |a XI 4403 |0 (DE-625)153006:12909 |2 rvk | ||
| 084 | |a 610 |2 sdnb | ||
| 245 | 1 | 0 | |a Iloprost in intensive care medicine |c [Ralf Ewert. In collab with Ragnar Gareis ...] |
| 264 | 1 | |a Bremen |b UNI-MED-Verl. |c 2006 | |
| 300 | |a 112 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a UNI-MED science | |
| 500 | |a Literaturangaben | ||
| 650 | 4 | |a Iloprost |x therapeutic use | |
| 650 | 4 | |a Intensive Care | |
| 650 | 0 | 7 | |a Iloprost |0 (DE-588)4226591-5 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Iloprost |0 (DE-588)4226591-5 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Ewert, Ralf |d 1957- |e Sonstige |0 (DE-588)132189410 |4 oth | |
| 700 | 1 | |a Gareis, Ragnar |e Sonstige |4 oth | |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016030022&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-016030022 | ||
Datensatz im Suchindex
| _version_ | 1804137104964321280 |
|---|---|
| adam_text | Contents
Contents
Pharmacology of Prostanoids
10
1.1.
Nomenclature, biochemistry and biosynthesis of eicosanoids
.............................10
1.2.
Pharmacology of
prostans
...............................................................13
1.3.
Basis of airbourne application for aerosol substances
.....................................17
1.4.
Pharmacology of airbourne applied lloprost
..............................................18
1.5.
Investigations into the stability of prostanoids in solution
.................................21
1.6.
References
...............................................................................23
^| lloprost for treatment in Peripheral Arterial Disease
32
2.1.
Introduction
.............................................................................32
2.2.
Acute limb ischaemia
....................................................................33
2.2.1.
Clinical presentation
..........................................................................33
2.2.2.
Further investigations
.........................................................................33
2.2.3.
Therapy
.......................................................................................33
2.3.
Chronic POAD
...........................................................................33
2.3.1.
Clinical presentation
..........................................................................33
2.3.2.
Physical examination
..........................................................................34
2.3.3.
Further investigations
.........................................................................34
2.4.
Therapy
.................................................................................35
2.4.1.
General considerations
........................................................................35
2.4.2.
Intermittent
claudication
......................................................................35
2.4.3.
Critical limb ischaemia
.........................................................................36
2.5.
Pharmacotherapy using lloprost in POAD
.................................................36
2.5.1.
Pharmacodynamics
...........................................................................36
2.5.2.
lloprost in critical limb ischaemia
..............................................................36
2.5.3.
Optimal lloprost dose
.........................................................................37
2.5.4.
Optimal daily duration of lloprost administration
...............................................37
2.5.5.
lloprost therapy during vascular reconstruction
................................................37
2.6.
Comparison of lloprost with Prostaglandin E1 in the treatment of critical limb ischaemia
... 39
2.7.
lloprost in the treatment of thromboangiitis obliterans
(Buerger s
disease)
................41
2.8.
Summary
................................................................................42
2.9.
References
...............................................................................42
ЦП
The use of lloprost in Patients with Pulmonary Hypertension
46
3.1.
Definition of Pulmonary Hypertension
....................................................46
3.2.
Historical development in the knowledge of pulmonary hypertension
.....................47
3.3.
Pathophysiology of PH
...................................................................47
3.4.
General recommendations for the treatment of PH
.......................................49
3.5.
Intravenous Prostanoids in Patients with PH
..............................................50
Contents 7
3.6. Dose
and choice of intravenous prostanoids
..............................................56
3.7.
Our own results with intravenous lloprost in the treatment of PH
..........................57
3.8.
Aerosolized administration of prostanoids in patients with PH
.............................59
3.9.
The use of further prostanoids for the treatment of PH
....................................64
3.10.
Evaluation of prostanoids in the treatment of PH
..........................................66
3.11.
References
...............................................................................67
Chronic heart failure and cardiopulmonary resuscitation of patients with
severe pulmonary hypertension
76
4.1.
Background
.............................................................................76
4.2.
Clinical experience with lloprost
..........................................................79
4.3.
The use of prostaglandins in the treatment of cardiac failure
..............................81
4.4.
Prostaglandins in the treatment of chronic cardiac failure
.................................81
4.5.
Prostaglandin in the testing of vasoreactivity in patients with pulmonary hypertension
and chronic cardiac failure
...............................................................82
4.6.
Prostaglandins in the
penoperative
treatment of patients with chronic heart failure
........83
4.7.
References
...............................................................................83
Use of lloprost in sepsis and haemodialysis
86
5.1.
Introduction
.............................................................................86
5.2.
Basic experimental concepts
.............................................................86
5.2.1.
Sepsis
.........................................................................................87
5.2.2.
Haemodialysis
................................................................................88
5.3.
Sepsis
...................................................................................89
5.3.1.
Systemic administration
.......................................................................89
5.3.2.
Regional administration
.......................................................................91
5.3.3.
lnhalative administration
......................................................................91
5.4.
Haemodialysis
...........................................................................92
5.4.1.
Combined administration with heparin
........................................................92
5.4.2.
Heparin-induced thrombocytopenia
...........................................................93
5.4.3.
Administration as heparin-replacement
........................................................94
5.5.
Contraindications
........................................................................94
5.5.1.
Relative contraindications
.....................................................................94
5.5.2.
Absolute contraindications
....................................................................94
5.5.3.
Temporary contraindications
..................................................................94
5.6.
Summary
................................................................................94
5.7.
References
...............................................................................94
ВЦ
Perioperative
Use of lloprost during Liver Transplantation
98
6.1.
Introduction
.............................................................................98
6.2.
Cardiopulmonary dysfunction in patients prior to
OLT
....................................98
6.3.
lloprost during
OLT
......................................................................99
6.4.
References
.............................................................................100
Contents
Postoperative pulmonary hypertension in children with congenital heart
disease
102
7.1.
Introduction
............................................................................102
7.2.
Pathophysiological background and standard therapeutic options
.......................103
7.2.1.
Preoperative
pulmonary endothelia! dysfunction
.............................................103
7.2.2.
Effect of cardiopulmonary bypass and endothelins
............................................103
7.2.3.
Right ventricular afterload increase
...........................................................104
7.2.4.
Pulmonary hypertensive crisis
................................................................104
7.2.5.
Problems of traditional treatment strategies
..................................................104
7.3.
Methods of application and judgement of its effect
......................................105
7.3.1.
Inhalation of pulmonary vasodilators
.........................................................105
7.3.2.
Central venous pressure
......................................................................105
7.3.3.
Pulmonary arterial pressure, right ventricular function, and cardiac output
.....................105
7.3.4.
Measurement of pulmonary vascular resistance
...............................................106
7.3.5.
Pulmonary gas exchange and transcutaneously measured saturation
..........................106
7.3.6.
Pulmonary mechanics
........................................................................107
7.4.
Clinical application of different vasodilators
.............................................107
7.4.1.
Comparison of prostanoids with NO
..........................................................107
7.4.2.
Combination therapy
........................................................................108
7.5.
Special aspects
.........................................................................108
7.5.1.
Application of treatments strategy
............................................................108
7.5.2.
Spill-over
....................................................................................108
7.5.3.
Special circulations
...........................................................................108
7.5.4.
Future combinations
.........................................................................108
7.6.
References
.............................................................................109
■I Index
111
|
| adam_txt |
Contents
Contents
Pharmacology of Prostanoids
10
1.1.
Nomenclature, biochemistry and biosynthesis of eicosanoids
.10
1.2.
Pharmacology of
prostans
.13
1.3.
Basis of airbourne application for aerosol substances
.17
1.4.
Pharmacology of airbourne applied lloprost
.18
1.5.
Investigations into the stability of prostanoids in solution
.21
1.6.
References
.23
^| lloprost for treatment in Peripheral Arterial Disease
32
2.1.
Introduction
.32
2.2.
Acute limb ischaemia
.33
2.2.1.
Clinical presentation
.33
2.2.2.
Further investigations
.33
2.2.3.
Therapy
.33
2.3.
Chronic POAD
.33
2.3.1.
Clinical presentation
.33
2.3.2.
Physical examination
.34
2.3.3.
Further investigations
.34
2.4.
Therapy
.35
2.4.1.
General considerations
.35
2.4.2.
Intermittent
claudication
.35
2.4.3.
Critical limb ischaemia
.36
2.5.
Pharmacotherapy using lloprost in POAD
.36
2.5.1.
Pharmacodynamics
.36
2.5.2.
lloprost in critical limb ischaemia
.36
2.5.3.
Optimal lloprost dose
.37
2.5.4.
Optimal daily duration of lloprost administration
.37
2.5.5.
lloprost therapy during vascular reconstruction
.37
2.6.
Comparison of lloprost with Prostaglandin E1 in the treatment of critical limb ischaemia
. 39
2.7.
lloprost in the treatment of thromboangiitis obliterans
(Buerger"s
disease)
.41
2.8.
Summary
.42
2.9.
References
.42
ЦП
The use of lloprost in Patients with Pulmonary Hypertension
46
3.1.
Definition of Pulmonary Hypertension
.46
3.2.
Historical development in the knowledge of pulmonary hypertension
.47
3.3.
Pathophysiology of PH
.47
3.4.
General recommendations for the treatment of PH
.49
3.5.
Intravenous Prostanoids in Patients with PH
.50
Contents 7
3.6. Dose
and choice of intravenous prostanoids
.56
3.7.
Our own results with intravenous lloprost in the treatment of PH
.57
3.8.
Aerosolized administration of prostanoids in patients with PH
.59
3.9.
The use of further prostanoids for the treatment of PH
.64
3.10.
Evaluation of prostanoids in the treatment of PH
.66
3.11.
References
.67
Chronic heart failure and cardiopulmonary resuscitation of patients with
severe pulmonary hypertension
76
4.1.
Background
.76
4.2.
Clinical experience with lloprost
.79
4.3.
The use of prostaglandins in the treatment of cardiac failure
.81
4.4.
Prostaglandins in the treatment of chronic cardiac failure
.81
4.5.
Prostaglandin in the testing of vasoreactivity in patients with pulmonary hypertension
and chronic cardiac failure
.82
4.6.
Prostaglandins in the
penoperative
treatment of patients with chronic heart failure
.83
4.7.
References
.83
Use of lloprost in sepsis and haemodialysis
86
5.1.
Introduction
.86
5.2.
Basic experimental concepts
.86
5.2.1.
Sepsis
.87
5.2.2.
Haemodialysis
.88
5.3.
Sepsis
.89
5.3.1.
Systemic administration
.89
5.3.2.
Regional administration
.91
5.3.3.
lnhalative administration
.91
5.4.
Haemodialysis
.92
5.4.1.
Combined administration with heparin
.92
5.4.2.
Heparin-induced thrombocytopenia
.93
5.4.3.
Administration as heparin-replacement
.94
5.5.
Contraindications
.94
5.5.1.
Relative contraindications
.94
5.5.2.
Absolute contraindications
.94
5.5.3.
Temporary contraindications
.94
5.6.
Summary
.94
5.7.
References
.94
ВЦ
Perioperative
Use of lloprost during Liver Transplantation
98
6.1.
Introduction
.98
6.2.
Cardiopulmonary dysfunction in patients prior to
OLT
.98
6.3.
lloprost during
OLT
.99
6.4.
References
.100
Contents
Postoperative pulmonary hypertension in children with congenital heart
disease
102
7.1.
Introduction
.102
7.2.
Pathophysiological background and standard therapeutic options
.103
7.2.1.
Preoperative
pulmonary endothelia! dysfunction
.103
7.2.2.
Effect of cardiopulmonary bypass and endothelins
.103
7.2.3.
Right ventricular afterload increase
.104
7.2.4.
Pulmonary hypertensive crisis
.104
7.2.5.
Problems of traditional treatment strategies
.104
7.3.
Methods of application and judgement of its effect
.105
7.3.1.
Inhalation of pulmonary vasodilators
.105
7.3.2.
Central venous pressure
.105
7.3.3.
Pulmonary arterial pressure, right ventricular function, and cardiac output
.105
7.3.4.
Measurement of pulmonary vascular resistance
.106
7.3.5.
Pulmonary gas exchange and transcutaneously measured saturation
.106
7.3.6.
Pulmonary mechanics
.107
7.4.
Clinical application of different vasodilators
.107
7.4.1.
Comparison of prostanoids with NO
.107
7.4.2.
Combination therapy
.108
7.5.
Special aspects
.108
7.5.1.
Application of treatments strategy
.108
7.5.2.
Spill-over
.108
7.5.3.
Special circulations
.108
7.5.4.
Future combinations
.108
7.6.
References
.109
■I Index
111 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author_GND | (DE-588)132189410 |
| building | Verbundindex |
| bvnumber | BV022824720 |
| classification_rvk | XI 4403 |
| ctrlnum | (OCoLC)71336777 (DE-599)BVBBV022824720 |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01666nam a2200445 c 4500</leader><controlfield tag="001">BV022824720</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20071107 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">070926s2006 gw ad|| |||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">06,A42,1105</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">981190383</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783895999437</subfield><subfield code="c">Pp. : EUR 44.80, sfr 79.20</subfield><subfield code="9">978-3-89599-943-7</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3895999431</subfield><subfield code="c">Pp. : EUR 44.80, sfr 79.20</subfield><subfield code="9">3-89599-943-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)71336777</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV022824720</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 4403</subfield><subfield code="0">(DE-625)153006:12909</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Iloprost in intensive care medicine</subfield><subfield code="c">[Ralf Ewert. In collab with Ragnar Gareis ...]</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bremen</subfield><subfield code="b">UNI-MED-Verl.</subfield><subfield code="c">2006</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">112 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">UNI-MED science</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Literaturangaben</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Iloprost</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Intensive Care</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Iloprost</subfield><subfield code="0">(DE-588)4226591-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Iloprost</subfield><subfield code="0">(DE-588)4226591-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ewert, Ralf</subfield><subfield code="d">1957-</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)132189410</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gareis, Ragnar</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016030022&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016030022</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV022824720 |
| illustrated | Illustrated |
| index_date | 2024-07-02T18:41:22Z |
| indexdate | 2024-07-09T21:07:00Z |
| institution | BVB |
| isbn | 9783895999437 3895999431 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016030022 |
| oclc_num | 71336777 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 112 S. Ill., graph. Darst. |
| publishDate | 2006 |
| publishDateSearch | 2006 |
| publishDateSort | 2006 |
| publisher | UNI-MED-Verl. |
| record_format | marc |
| series2 | UNI-MED science |
| spelling | Iloprost in intensive care medicine [Ralf Ewert. In collab with Ragnar Gareis ...] Bremen UNI-MED-Verl. 2006 112 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier UNI-MED science Literaturangaben Iloprost therapeutic use Intensive Care Iloprost (DE-588)4226591-5 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Iloprost (DE-588)4226591-5 s DE-604 Ewert, Ralf 1957- Sonstige (DE-588)132189410 oth Gareis, Ragnar Sonstige oth Digitalisierung UB Regensburg application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016030022&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Iloprost in intensive care medicine Iloprost therapeutic use Intensive Care Iloprost (DE-588)4226591-5 gnd |
| subject_GND | (DE-588)4226591-5 (DE-588)4143413-4 |
| title | Iloprost in intensive care medicine |
| title_auth | Iloprost in intensive care medicine |
| title_exact_search | Iloprost in intensive care medicine |
| title_exact_search_txtP | Iloprost in intensive care medicine |
| title_full | Iloprost in intensive care medicine [Ralf Ewert. In collab with Ragnar Gareis ...] |
| title_fullStr | Iloprost in intensive care medicine [Ralf Ewert. In collab with Ragnar Gareis ...] |
| title_full_unstemmed | Iloprost in intensive care medicine [Ralf Ewert. In collab with Ragnar Gareis ...] |
| title_short | Iloprost in intensive care medicine |
| title_sort | iloprost in intensive care medicine |
| topic | Iloprost therapeutic use Intensive Care Iloprost (DE-588)4226591-5 gnd |
| topic_facet | Iloprost therapeutic use Intensive Care Iloprost Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016030022&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT ewertralf iloprostinintensivecaremedicine AT gareisragnar iloprostinintensivecaremedicine |